Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over losses of $(1.07) per share from the same period last year. The company reported quarterly sales of $58.301 million which beat the analyst consensus estimate of $57.028 million by 2.23 percent. This is a 104.43 percent increase over sales of $28.519 million the same period last year.